Ann Arbor, Mich. October 27, 2020 — Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has established coverage of the StrataNGSTM test for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/ or metastatic solid tumors.
StrataNGSTM is a comprehensive genomic profiling (CGP) test that features leading performance on small tumor tissue samples. The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.
A recent study presented at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) showed that the performance of StrataNGS on small tumor tissue samples may enable access to testing for more than double the number of patients compared to other leading comprehensive genomic profiling (CGP) tests. The results from an analysis of data collected in the Strata Trial demonstrated that only 43 percent of >20,000 consecutive tumor tissue samples received for CGP met tissue surface area requirements for leading commercial hybrid-capture-CGP tests. StrataNGS, a PCR-CGP test, delivered reportable results in 93 percent of all samples received.
Read more here.